Adicet Bio, Inc. Debt Securities, Available-for-sale, Amortized Cost
Adicet Bio, Inc. (ACET) had Debt Securities, Available-for-sale, Amortized Cost of $85.16 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $85.16M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $101.38M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $119.51M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $73.94M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $85.16M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $101.38M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $119.51M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $73.94M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $90.28M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $122.31M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $119.79M 10-K · filed 2026-03-12 | |
| 2021-03-31 | $1.75M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $10.26M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $23.08M 10-Q · filed 2020-11-05 | |
| 2020-03-31 | $15.08M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $62.36M 10-K · filed 2021-03-12 | $57.65M 10-K · filed 2020-03-12 |
| 2019-09-30 | $93.53M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $111.25M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $135.88M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $101.03M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $92.60M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $74.60M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |